Does erythropoietin administration affect progression of atherosclerosis in Watanabe heritable hyperlipaemic rabbits?
Buemi
M
M
Allegra
A
A
Corica
F
F
Calapai
G
G
Cavallaro
G
G
Aloisi
C
C
Pettinato
G
G
Russo
A
A
Frisina
N
N
D000818:Animals; D001011:Aorta / Q000378:metabolism / Q000473:pathology; D001018:Aortic Diseases / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*; D001161:Arteriosclerosis / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*; D002788:Cholesterol Esters / Q000378:metabolism; D004195:Disease Models, Animal; D018450:Disease Progression; D004921:Erythropoietin / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000235:genetics; D008055:Lipids / Q000097:blood; D008297:Male; D011817:Rabbits; D011994:Recombinant Proteins
D002788:Cholesterol Esters; D008055:Lipids; D011994:Recombinant Proteins; D004921:Erythropoietin